Loading stock data…
LMAT
$96.59+1.48 (+1.56%)
After Hours$96.59+0.00 (+0.00%)· Last close Jun 9
LeMaitre Vascular, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LeMaitre Vascular, Inc. in the Healthcare sector is trading at $96.59 with a market capitalization of $2.1B. Wall Street consensus targets $118.75 (8 analysts), implying a +22.9% move over the next 12 months. The stock is currently 18% below its 52-week high of $118.01, remaining 2.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +22.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$96.59
Potential Upside
30.9%
Whystock Fair Value$126.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$118.75+22.9%
Range$102.00 – $135.00
Fundamentals
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreser...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.69
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.67%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.35%
Volume
Today's trading volume
423,076
Recent News
3 of Wall Street’s Favorite Stocks We Find Risky
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
How The LeMaitre Vascular (LMAT) Story Is Shifting As Analysts Lift Fair Value Targets
The fair value price target for LeMaitre Vascular has been updated to US$118.75 from US$111.22, giving you a fresh reference point for what analysts think the stock could be worth on their models. That shift sits alongside a cluster of higher targets from bullish research houses and at least one more neutral call, so you are seeing both enthusiasm and caution reflected in the numbers. Read on to see what is driving this evolving narrative and how you can follow it as new research comes...
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
1 Reason to Avoid LMAT and 1 Stock to Buy Instead
LeMaitre has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 15.5% to $101.53 per share while the index has gained 11.3%.
Winners And Losers Of Q1: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including LeMaitre (NASDAQ:LMAT) and its peers.